342 results about "Pharmaceutical Excipient" patented technology

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

The invention relates to the technical field of biological medicine, in particular to a ferroptosis inhibition type phospholipid-like material and application thereof. The ferroptosis inhibition type phospholipid-like material is one of the following structural general formulas (1)-(5). The biomimetic phospholipid-like ferroptosis inhibitor has a long retention characteristic in main positions (cell membranes, endoplasmic reticulum and other organelle membranes) of cell ferroptosis, so that the ferroptosis inhibition efficiency is remarkably improved. The novel phospholipid-like material not only can be used as an active drug molecule, but also can be used as a pharmaceutic adjuvant for constructing drug delivery carriers such as lipidosome and micelle and implant coatings, and is suitable for various administration routes such as oral administration, injection and local administration. The novel biomimetic ferroptosis inhibitor can efficiently relieve cell ferroptosis and has a wide application prospect in the field of treating or retarding ferroptosis-related diseases.

There is provided a compound of Formula I, wherein: Qa represents Z or A-Q-B, and Q is a structural fragment of Formula II,wherein: the squiggly lines, R and m have meanings given in the description, and wherein A and B have meanings given in the description, but may represent a peptide component of Formula (IV),[(W)r-Lys-X1-T-U-X2-Y] n- (W)r-Lys-X1-T-U-X2-Y (IV) (SEQ ID No: 1) in which n, r, T, W, X1, U, X2 and Y have meanings given in the description, each L independently represents a lipid as defined in the description, and D represents one or more optional montelukast moieties, which compounds are useful in medicine, including as pharmaceutical excipients, adhesives and film-forming materials and / or are useful in the treatment of conditions characterised by inflammation, including wounds, burns, and disorders of the mucosa, such as anorectal diseases, inflammatory bowel diseases, gynecological diseases and dental diseases.

Provided herein are pharmaceutical compositions comprising a compound of having Formula I as described in this disclosure, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutical excipients, wherein the composition is in a unit dosage form; and methods for treating cancer modulated by HER2 in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition or a compound having Formula II as described in this disclosure, or a pharmaceutically acceptable salt thereof, and optionally one or more additional therapeutic agents.

Provided is a compound of formula I, X-Y (I) wherein: Y comprises a peptide fragment of formula IV, [Ala] m-[Lys-V]n-Lys-V (IV) in which m represents 0 or 1, n represents an integer 0, 1, 2, 3 or 4 and, each V independently represents a 2 to 4 amino acids sequence, in which the amino acids are selected from one or more of the group Lys, Pro, Hyp, diHyp, Thr, pThr, DOPA, Tyr, and Ser; and X represents at least one optional substituent selected from: (i)a lipid, which lipid is selected from the group consisting of vitamin A, vitamin E, cholesterol and a fatty acid; and / or (ii)a non-steroidal anti-inflammatory drug, which compounds are useful in medicine, including as pharmaceutical excipients, adhesives and film-forming materials and / or are useful in the treatment of conditions characterised by inflammation, including wounds, burns, and disorders of the mucosa, such as skin diseases, oral diseases, gynecological diseases and IBDs.

The invention firstly discloses application of portulaca oleracea polysaccharide in preparation of the medicine for treating psoriasis, the medicine for treating psoriasis can improve psoriasis-like skin injury and reduce skin tissue inflammation, and the portulaca oleracea polysaccharide is single-component pure polysaccharide extracted from portulaca oleracea and purified. The monosaccharide composition is composed of all or several monosaccharides of rhamnose, arabinose, galactose, glucose, xylose and galacturonic acid, and the molecular weight of the monosaccharide composition is 80-200 kDa. The invention further discloses application of the purslane polysaccharide in preparation of drugs for treating psoriasis and application of the purslane polysaccharide in preparation of cosmetics and medical auxiliary materials for relieving psoriasis-like skin injury. The purslane polysaccharide disclosed by the invention is high in purity, clear in structure and high in safety, has a good psoriasis treatment effect, is superior to dexamethasone in curative effect, can be used as a skin external medicine, a cosmetic, a medical instrument and a medical auxiliary material, and has various potential application values.

The invention belongs to the technical field of biological fermentation, and particularly relates to a preparation method and application of a high-activity antioxidant product based on hericium erinaceus-hawthorn solid state fermentation. Activating the strain to prepare a seed solution; adding hawthorn into the rice solid culture medium, inoculating hericium erinaceus, performing constant-temperature culture, drying a fermentation product to constant weight at normal temperature and normal pressure after the culture is finished, crushing, and sieving for later use. The antioxidant effect of the fermentation product is comprehensively evaluated and verified through a systematic in-vitro chemical antioxidant experiment (ABTS < + >, DPPH free radical and hydroxyl free radical scavenging) and an in-vivo zebra fish oxidative stress model, and solid data support is provided for application of the fermentation product in healthy products. The resource high-value utilization way of the hawthorn and the hericium erinaceus is widened, and a technical scheme and a product prototype are provided for developing novel food raw materials, health-care products or medicine auxiliary materials with definite antioxidant functions.

The invention discloses a mussel mucoprotein extraction and purification method, which comprises: 1) taking mussel foot glands, adding an extraction liquid 1, soaking, homogenizing, precipitating, taking the precipitate, adding an extraction liquid 2, re-suspending, homogenizing, carrying out centrifugal filtration, and taking the filtrate to obtain an extract; and 2) purifying the extract obtained in the step 1). The mussel mucoprotein obtained by extracting through a specific extracting solution and then adopting a specific purification method is high in protein and dopa content, can be compatible with pharmaceutical auxiliary materials such as anionic polymer components carbomer, sodium hyaluronate and sodium carboxymethyl cellulose, is used for preparing medicines or skin care products, and is wide in application prospect.

The invention discloses a ketotifen fumarate divided-dose tablet based on a 3D printing technology and a preparation method thereof. The ketotifen fumarate clinical divided-dose tablet comprises the following components in percentage by mass: 1-10% of ketotifen fumarate tablet powder, 90-99% of cocoa butter and 0-5% of a flavoring agent, and the sum of the mass percentages of the components is equal to 100%. According to the technical scheme, a hot-melt extrusion type 3D printing technology is adopted to achieve rapid dissolution and clinical precise dose division of tablets, the 3D printing technology is applied to the field of dose division of commercially available tablets, and tablet powder and heated and melted pharmaceutic adjuvants are evenly mixed to prepare a printing material; the dose of the 3D printing divided dose tablet is accurately controlled by adjusting the drug content of the printing material and the volume of the printing model; the content of medicines in commercially available tablets is diluted by adding pharmaceutic adjuvants, and small-dose tablets with lower content are prepared again, so that precise dose-divided administration is realized, and the purpose of individualized administration is achieved.

Disclosed in the present invention are a preparation method for a brain-targeting agomelatine nasal spray micelle and use thereof, which belong to the technical field of pharmaceutical formulations. According to the present invention, an injectable pharmaceutical excipient polyethylene glycol (15)-hydroxystearate (HS15) is taken as a carrier material, HS15 and agomelatine are dissolved in an organic solvent, and the resulting solution is subjected to rotary evaporation under reduced pressure to form a uniform film, which, upon hydration, forms an agomelatine micelle solution capable of being sprayed nasally for treating depression and insomnia. According to the present invention, the problem of low oral bioavailability of agomelatine due to poor solubility, serious first pass effect of hepar, difficulty in penetrating a blood-brain barrier, etc., is solved. The micelle structure constructed in the present invention is quickly delivered into the brain after nasal administration, and it is stable in cerebrospinal fluid and can achieve slow release of the drug, thereby improving the intracerebral bioavailability of the drug and achieving high brain targeting property and low systemic toxic and side effects. The micelle structure has good clinical application value and market prospects.

The present invention relates to a computer-implemented method for preparing multiple dosage forms with personalised composition, comprising the following steps:(i) a control unit generates an input protocol of a personalised composition of a multiple dosage form, containing information about the type and amount of individual active substances, the type of cartridge, and the type and number of capsules;(ii) a cartridge of the required type according to the input protocol, labelled with a specific machine-readable code, is placed in the automatic transport system;(iii) at least two different types of sub-units are placed into at least two dosing stations, the sub-unit having sizes in the range of from 0.1 to 4 mm, and containing a different active ingredient and / or different amounts of the same active ingredient and / or having coatings with different solubility and / or possibly containing different pharmaceutical excipients according to the input protocol;(iv) a pre-defined number of capsule bodies is placed in the cartridge placed in an automatic transport system;(v) the automatic transport system transports the cartridge with capsules to the first dosing station, which doses a pre-defined number of the first sub-units into the capsule bodies placed in the cartridge;(vi) the automatic transport system transports the cartridge with capsules to the next dosing station, which doses a pre-defined number of the next sub-units into the capsule bodies placed in the cartridge; and this step is repeated according to the input protocol until the capsules are filled with all of the pre-defined types of sub-units;(vii) the capsules are closed with caps;(viii) the quality control of capsules and discarding of the non-compliant ones;(ix) packaging and labelling with a batch number.The present invention further relates to a device for carrying out this method.

The invention provides a briracetam sustained-release pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition comprises a pharmaceutical active ingredient and a pharmaceutical excipient, wherein the pharmaceutical excipient is selected from one or more of a framework material, a disintegrating agent, a swelling agent, an adhesive, a filler and a lubricant. The briracetam sustained-release pharmaceutical composition disclosed by the invention is good in sustained-release effect, stable in release speed and small in side effect, the medicine taking frequency is reduced, and the compliance of a patient is improved; the retention time of the medicine in the stomach is prolonged, so that the medicine is continuously released in the stomach and is absorbed at the upper end of the small intestine, the effect of continuously taking effect for 24 hours is achieved, the plasma concentration is stable, and the adverse reaction is small; a patient is prevented from randomly interrupting medication, and disease relapse and malignant complication development are prevented; the medicine is few in administration times, convenient to take and small in toxic and side effects.

A pharmaceutical composition or a pharmaceutical preparation, the pharmaceutical composition or the pharmaceutical preparation comprising a therapeutically effective amount of an active ingredient M and a pharmaceutical excipient, the active ingredient M being selected from a compound of general formula (I) or a stereoisomer, a tautomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or eutectic thereof, the pharmaceutical composition or the pharmaceutical preparation comprises 1-600 mg of an active ingredient M. The invention also relates to application of the pharmaceutical composition or the pharmaceutical preparation in preparation of related medicines for treating cancers.

The invention belongs to the field of pharmaceutical preparations. The invention relates to a novel dosage form of an isavuconazole sulfate freeze-dried tablet, and a prescription and a process for preparing the isavuconazole sulfate freeze-dried tablet by adopting a freeze-drying method. The isavuconazole sulfate freeze-dried tablet is prepared from isavuconazole sulfate serving as a main drug and pharmaceutic adjuvants. Water is not needed during taking, and the tablet can be rapidly disintegrated after being put in the mouth and is suitable for patients with dysphagia such as old people and children; the production process of the isavuconazole sulfate freeze-dried orally disintegrating tablet is simple in technology, easy to control and suitable for industrial production.

This invention discloses an energy-saving control system for drying equipment based on multidimensional factor analysis, belonging to the field of intelligent control technology. The system includes: interactively obtaining the pre-drying material characteristics of the pharmaceutical excipients to be dried; pre-constructing a material drying optimization space; locating initial drying control parameters; obtaining multiple sets of equipment parameter adjustment values ​​mapped to multiple drying stages; performing drying simulations on the pharmaceutical excipients to be dried using stage moisture content as a constraint, obtaining multiple sets of drying times, multiple sets of equipment energy consumption, and multiple sets of excipient loss rates; obtaining a target drying control array; and running the drying equipment to perform low-energy drying of the pharmaceutical excipients to be dried. This invention solves the technical problems of existing energy-saving control systems for drying equipment, which rely on fixed parameters and are difficult to accurately match the changes in the characteristics of different pharmaceutical excipients, leading to increased energy consumption and insufficient drying quality and efficiency of pharmaceutical excipients. It achieves the technical effects of effectively reducing energy consumption, improving drying efficiency, and enhancing product quality stability.

The invention provides a probiotic fermentation and bacterial powder compound addition chewable tablet and a preparation method thereof, and belongs to the technical field of microorganisms, the preparation method comprises the following steps: respectively adding water into apple peel, cerasus humilis fruits and aronia melanocarpa fruits, pulping, and mixing in proportion to obtain mixed fruit pulp; a mixed bacterium solution of lactobacillus plantarum LNJ-HQ-01 and lactobacillus fermentum BNCC194390 is added into the mixed fruit pulp, and fermentation is performed; freeze-drying and grinding the fermented fruit pulp to obtain freeze-dried fruit powder; the preparation method comprises the following steps: respectively activating lactobacillus plantarum LNJ-HQ-01, lactobacillus acidophilus BNCC186447 and lactobacillus rhamnosus ATCC7469, performing enlarged culture, taking bacterial sludge, uniformly mixing the bacterial sludge with a freeze-drying protective additive, and performing freeze-drying to obtain freeze-dried bacterial powder; and uniformly mixing the fruit powder, the freeze-dried bacterial powder and the medicinal auxiliary materials, and tabletting to obtain the probiotic chewable tablets. The probiotic chewable tablet is high in dietary fiber content, effective calcium content and total phenol content, high in oxidation resistance and suitable for calcium supplement of special groups such as diabetics and the like.

To provide a pomalidomide-containing pharmaceutical with improved elution behavior.SOLUTION: According to one embodiment of the present invention, a method for producing pomalidomide-containing pharmaceutical includes a step of co-grinding pomalidomide and solid pharmaceutical excipients with a rotary grinder.SELECTED DRAWING: Figure 1

The invention relates to the technical field of analytical chemistry detection, in particular to a method for determining trace nitrite in pharmaceutic adjuvants.The method comprises the steps that an acetonitrile solution, a potassium hydroxide solution, a phosphate buffer solution, a sulfuric acid solution, a 2, 3-diaminonaphthalene solution and a reference substance working solution are provided; the method comprises the following steps: preparing a standard curve solution and a test sample solution, and carrying out ultra-high performance liquid chromatography-tandem mass spectrometry analysis detection: respectively carrying out sample injection detection on the test sample solution and the prepared standard curve solutions with different concentrations under preset chromatographic conditions and mass spectrometry conditions, recording detection results of the standard curve solutions with different concentrations to make a standard curve, and calculating the content of nitrite in the test solution by adopting a standard addition method according to the standard curve and the detection result of the test solution. The method disclosed by the invention can be used for rapidly determining trace nitrite in a drug sample, and can be used for determining the trace nitrite in pharmaceutical adjuvants and detecting the nitrite in drugs.

Described herein is a computer-implemented method for training a machine learning model for predicting one or more physiochemical properties of a nanoparticle. In some instances, the method includes receiving a set of data including nanoparticles, generating a descriptor and fingerprint for each nanoparticle in the set of data, creating a plurality of sets of training data and a plurality of sets of test data, training a machine learning model of an artificial intelligence (AI) system using the plurality of sets of training data, and predicting a property of the drug-excipient pair of the plurality of sets of test data based on drug-excipient pairs and property values of each drug-excipient pair of the plurality of sets of training data. Also described herein are excipients conjugated to a polyethylene glycol moiety, or pharmaceutically acceptable salts thereof. In some instances, the excipients may be used to form nanoparticles with a therapeutic compound.

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

The invention discloses an aromatic propionic acid derivative as well as a preparation method, a pharmaceutical composition and application thereof. The invention specifically discloses a compound shown in a formula (I) or pharmaceutically acceptable salt thereof. The invention further discloses a pharmaceutical composition which comprises the compound shown in the formula (I), pharmaceutically acceptable salt of the compound and pharmaceutic adjuvants. The invention also discloses application of the compound as shown in the formula (I), the pharmaceutically acceptable salt of the compound or the pharmaceutical composition in preparation of drugs, and the drugs have GPR40 receptor agonistic activity and have one or more of the advantages of good activity, high targeting property, low toxicity and the like. # imgabs0 #

This utility model discloses a drying and sealing storage chamber for pharmaceutical excipients, including a chamber body and a storage rack. The top of the chamber body has two slots, each with a drying frame inserted into its inner side. Each drying frame has an opening at its top and a movable plate is detachably connected via bolts. The left and right drying frames are fixedly connected by a lifting frame. Two partitions are fixedly connected to the inner side of the chamber body, each partition having three ventilation slots on its surface. A fan is installed inside each ventilation slot. This utility model, by providing a detachable drying frame at the top of the chamber body, combined with the lifting frame, allows for complete removal and replacement of the desiccant without opening the chamber body. This avoids external environmental interference with the internal drying process. Compared to traditional fixed drying structures, it achieves flexible switching between drying and ventilation, improving operational efficiency.

The present invention relates to a pharmaceutical composition containing alkynyl compound, a preparation method thereof and its application. The present invention discloses a pharmaceutical composition comprising an active pharmaceutical ingredient and an available pharmaceutical excipient; The active pharmaceutical ingredient is 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-benzamide, or its pharmaceutical acceptable salt; The available pharmaceutical excipients includes diluents and lubricants. The pharmaceutical composition can effectively improve the bioavailability of the alkynyl compound, has good dissolution and stability, and improve the drug safety.

The utility model discloses novel crushing equipment for medicinal auxiliary material production, which comprises a crushing box, the inner wall of the crushing box is respectively and rotatably connected with two crushing rollers, the two crushing rollers can oppositely rotate to crush auxiliary materials, one side of the crushing box is fixedly connected with a crushing motor, and the other side of the crushing box is fixedly connected with the crushing motor. The output end of the smashing motor penetrates through the inner wall of the smashing box and is fixedly connected with the smashing rollers, two sets of brushes corresponding to the smashing rollers are arranged on the inner wall of the smashing box, each brush comprises a mounting base arranged on the inner wall of the smashing box, and bristles are fixedly connected to the surfaces of the mounting bases; the bristles are attached to the smashing rollers to brush off auxiliary materials attached to the surfaces of the smashing rollers. According to the novel crushing equipment for producing the pharmaceutical excipients, the brushes are arranged, when the two crushing rollers rotate to crush the excipients, the bristles brush off the excipients attached to the surfaces of the crushing rollers, waste is reduced, and therefore the novel crushing equipment for producing the pharmaceutical excipients has the effect of reducing waste of the excipients.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a minoxidil external preparation composition as well as a preparation method and application thereof. The invention provides a minoxidil external preparation composition. The minoxidil external preparation composition comprises minoxidil, finasteride, pharmaceutic adjuvants, organic acid, ethanol and water. By adding finasteride and pharmaceutic adjuvants, the treatment effect on alopecia is enhanced; by adding a proper amount of organic acid, the dissolution of minoxidil can be promoted in the absence of propylene glycol, so that the problem of replacing a propylene glycol solvent is solved. The minoxidil external composition prepared by the invention is stable, the treatment effect of the minoxidil external composition on alopecia is obviously higher than that of a solution only containing a minoxidil single component, and the minoxidil external composition does not contain a propylene glycol component, so that the occurrence of propylene glycol allergy is avoided. And the preparation method is simple, stable and good in reproducibility.

The invention discloses an application of indole-3-formaldehyde in preparation of antidepressant drugs, and relates to the technical field of medicines.The antidepressant drugs comprise active ingredients and pharmaceutical excipients, the active ingredients comprise indole-3-formaldehyde or pharmaceutically acceptable salts thereof, and the effective dose of the active ingredients in rats is 70-200 mg / kg; indole-3-formaldehyde is adopted, so that depression-like behaviors of mice can be remarkably improved, the indole-3-formaldehyde can be used as an exogenous oral supplement to enter intestinal tracts and even can penetrate through a blood brain barrier to enter brain tissues, and the anti-depression effect is achieved from the two aspects of improving the intestinal steady state and protecting neuroinflammation. The tryptophan intestinal metabolite is applied to treatment and improvement of depression for the first time, and a theoretical basis and a novel angle are provided for subsequent research and development of antidepressant drugs applying the tryptophan intestinal metabolite.

A tizanidine liquid preparation and use of the tizanidine liquid preparation in the preparation of a medicament for treating muscle spasm, wherein the tizanidine liquid preparation comprises an active ingredient, a stabilizing agent and other pharmaceutical excipients, wherein the active ingredient is one or more of tizanidine or a pharmaceutically acceptable salt, solvate and hydrate thereof.

The invention discloses a carrier cooperation system, application and a preparation method of a dihydrocodeine tartrate tablet, the carrier cooperation system comprises a mesoporous silica carrier and a hydroxypropyl trimethyl ammonium chloride chitosan modification layer, the surface of the mesoporous silica carrier is modified by silicon hydroxyl, and the hydroxypropyl trimethyl ammonium chloride chitosan modification layer is adsorbed in a pore channel of mesoporous silica. A mesoporous silica carrier modified by hydroxypropyl trimethyl ammonium chloride chitosan is formed; the silicon hydroxyl of the mesoporous silica carrier and the carboxyl of the active pharmaceutical ingredient form a hydrogen bond, and the quaternary ammonium group of the hydroxypropyl trimethyl ammonium chloride chitosan modified layer and the active pharmaceutical ingredient containing the tertiary amine group form an electrostatic complexing effect; according to the application of the carrier synergistic system in preparation of the abuse-preventing dihydrocodeine tartrate tablet, the tablet contains the carrier synergistic system, 6.67%-10.0% of dihydrocodeine tartrate and pharmaceutic adjuvants; the invention further discloses a specific preparation method, and the double effects of abuse prevention and slow release are synchronously achieved.

The application discloses a NO donor type ligustrazine derivative, a preparation method, a composition and application, and provides a NO donor type ligustrazine derivative and a preparation method thereof, and further provides a composition of different dosage forms prepared by mixing the NO donor type ligustrazine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical excipient, and application of the composition in preparation of a medicine for preventing or treating thromboembolic cardiovascular and cerebrovascular diseases and diseases caused by platelet aggregation.

The invention discloses a method for preparing 1,4-cyclohexane diisocyanate, and belongs to the technical field of synthesis of diisocyanate. The preparation method is a one-step method to complete the overall reaction, the reaction route is simple, the raw materials are easily available, the conditions are mild, the use of highly toxic gas phosgene and explosive sodium azide is avoided, the safety is good, the product purity is not less than 98.5%, and the yield is 75% based on 1,4-cyclohexane diformyl hydrazide, which is suitable for large-scale production and is suitable for the application of pharmaceutical excipients. The synthesis route aims to use conventional, easy-to-obtain and cheap chemical materials to produce cyclohexane diisocyanate under relatively mild conditions. The process production prospect is good and it is easy to promote large-scale industrialization.